In the article entitled “Serum Cellular Fibronectin and Matrix Metalloproteinase-9 as Screening Biomarkers for the Prediction of Parenchymal Hematoma After Thrombolytic Therapy in Acute Ischemic Stroke: A Multicenter Confirmatory Study” by Castellanos et al,1 the authors inadvertently omitted a conflicts-of-interest disclosure statement. The authors regret this error. The Disclosures section of the article should state the following:
“Dr Joaquín Serena, Dr Antoni Dávalos, Dr Mar Castellanos, and Dr José Castillo are joint patent holders of US Patent No. 20070005261 with the title ‘Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof.’ The other authors have nothing to disclose.”
The corrected version of this article can now be viewed online at http://stroke.ahajournals.org.
1 [Correction for Vol 38, Number 6, June 2007. Pages 1855–1859.]